Managing Dermatologic Toxicities with EGFR Targeted Therapies in NSCLC

Video content above is prompted by the following:

• Let's discuss dermatologic toxicities associated with EGFR-targeted therapies. What's your approach to managing these adverse events?
  • What prophylactic measures and early interventions have you found most effective in mitigating dermatologic toxicities?
  • How do you utilize oral antibiotics, topical treatments (such as lotions or creams), and systemic medications in your management plan?
  • How do you incorporate patient education and self-management techniques into your overall strategy?